Background: OSAS and COPD are often associated with day-time hypoxemia. Overlap Syndrome (OS), the association between both diseases, increases the risk of day-time hypoxemia. The aim of this study was to investigate the mechanisms which could justify the low oxygen level and the effect of CPAP. Methods: We performed a retrospective analysis in all patients referred to our institutes for suspected OSAS and who also underwent spirometry and blood gas analysis during our evaluation. Thus, 720 patients were selected. According to pulmonary function test parameters they were divided into 3 groups: OSAS (N Z 466,65%); OS (N Z 168,23%) and COPD (N Z 86,12%). In order to evaluate the differences between the three groups, ANOVA analyses were carried out, whereas a multivariate analysis was performed in order to evaluate which factors determine the diurnal PaO 2 . In 90 patients we also have the data on blood gas analysis after one year of CPAP treatment, so we evaluate the PaO 2 improvement in accordance with compliance to treatment in these patient subgroups. Results: The OS group showed a lower level of daytime PaO 2 compared with OSAS patients and T90 was higher in OS compared with OSAS. A multivariate analysis showed that in the OS diurnal PaO 2 correlated with age (b Z 0.20) and moreover with FEV 1 (b Z 0.31) and T90 (b Z 0.37), while in the OSAS a correlation was found with FEV 1 (b Z 0.11) and mostly with BMI (b Z 0.25), age and T90. In all patients with good compliance to CPAP day-time PaO 2 improved. Conclusions: Our data suggest that day-time hypoxemia in OSA patients is largely determined by the increase of body weight and severity of nocturnal hypoxia. However, CPAP therapy has been shown to improve daytime PaO 2 values both in OSAS and in OS. ª
Introduction
Obstructive Sleep Apnea (OSAS) is the most frequent sleeprelated breathing disorder and has a significant impact on nocturnal arterial oxygenation 1 but also on development of daytime hypoxemia. 2 The presence of sleep oxyhemoglobin desaturation has been recognized as a risk factor for developing pulmonary arterial hypertension, above all in patients affected by OSAS in conjunction with COPD. The coexistence of COPD and OSAS, known as Overlap Syndrome (OS), amounts to about 1% of adult males, and is known to increase the risk of systemic inflammation and cardiovascular diseases. 3, 4 In these patients the severity of nocturnal desaturation is higher than in patients affected by OSAS or COPD alone. Moreover, patients who have nocturnal hypoxemia often present a low level of PaO 2 during wakefulness, although the relationship between nocturnal desaturation and day-time PaO 2 is not well understood. However, what is known is that in COPD hypoxemia is associated with a reduction of quality of life, low-exercise tolerance, and increased risk of death 5 The treatment of severe hypoxemia with long-term oxygen therapy (LTOT) remains the only intervention that can be useful in hypoxemic COPD, while the role of nocturnal ventilation is still debated. Sleep has significant effects on respiration in healthy subjects and even in patients affected by pulmonary disease or sleepdisordered breathing. The reduction of ventilation due to a decrease of chemoreceptor sensitivity, muscle activity reduction and alveolar hypoventilation is well documented both in healthy subjects 6 and in patients with COPD, 7, 8 but few large-scale studies are available in order to investigate the relevance of obesity, sleep-disordered breathing and lung function on diurnal PaO 2 in patients affected by OS.
The aim of this study is to increase the knowledge of mechanisms which link the PaO 2 in wakefulness and in sleep in a population of OSAS, COPD and OS patients, but also to verify the impact of nocturnal ventilation in patients with sleep disorder breathing on the improvement of diurnal PaO 2 .
Materials and methods
We performed a retrospective analysis on the subset of subjects who referred to the sleep laboratories of University of Foggia and Fondazione Maugeri, Cassano Murge (Bari) from 2007 to 2011 for suspected OSAS and who in addition to nocturnal cardio-respiratory polygraphy, according to a physician's evaluation, also underwent spirometry, blood gas analysis and the 6-min walking test. Patients with central apnea, heart failure, Obesity Hypoventilation Syndrome, and other chronic pulmonary diseases such as fibrosis or neuromuscular diseases were not included in the study.
In accordance with the results of nocturnal polygraphy and pulmonary function tests the subjects were divided into three groups: OSASþ/COPD-(OSAS); OSASþ/COPDþ (OS); OSAS /COPDþ (COPD). The study was approved by the institutional ethics committee.
Polygraphy
Unattended cardio-respiratory overnight monitoring (Vitalnight 11, Germany) was performed during the patient's hospital stay in the sleep laboratory. Sleep stages were not evaluated while flow, snoring, sleep position, leg movements, SaO 2 and heart rate were recorded. Oro-nasal flow was measured by a nasal cannula, whereas abdominal and rib-cage movements were measured by pneumatic sensors and oxyhemoglobin saturation with a finger probe. Sleepdisordered breathing was quantified according to standard criteria, 9 in summary: obstructive apnea was defined as a reduction of the flow at 90%, lasting at least for 10 s with the presence of abdominal or thoracic movement, central apnea in absence of both. Hypopnea was identified when there was a 50% reduction of flow for 10 s or more followed by a 4% decrease of saturation. AHI was defined as a number value corresponding to apnea plus hypopnea divided by the hours of registration, Oxygen desaturation index (ODI) was the number of desaturation >4% divided by the hours of registration. The exam was considered to be valid if there were at least 6 h of registration. A manual score was performed the day after registration by two doctors (one for each center) expert in sleep disorder, both of whom respected the same criteria.
Six-minute walking test
The 6MWT was performed in accordance with standard guidelines 10 in a corridor which was 20 m long; meter-bymeter marks were made and two cones signaled the walk turn. Parameters such as BP, HR, SpO 2 , and the modified Borg scale were collected both during the early and late phases of the walk. When the test was terminated, the distance covered was calculated using the notes of the number of turns performed by the patient.
Blood gas analysis and AaDO 2
The arterial blood sample for the analysis of gases during room-air breathing was drawn with the patient in a sitting position on the day after the polygraphy registration and within 1 h of waking up. PaO 2 , PaCO 2 and pH were measured in a blood gas analyzer (Model 1312; Instrumentation Laboratory; Milan, Italy). The alveolar-arterial difference (AaDO 2 ) was calculated by the equation: 150-(PaCO 2 /0.8)-PaO 2 .
Pulmonary function testing
Pulmonary function tests were performed in the pulmonary function laboratory of our Institutes using a spirometer (Sensormedics, USA). The equipment was calibrated daily using a 3-L syringe. The best of three reproducible spirometric values was expressed as a percentage of the predicted normal value; spirometry was repeated 15 min after the subject had inhaled 400 mg of salbutamol. Patients with a positive reversibility test (FEV 1 post-bronchodilatator better than 12% pre-bronchodilatator) were not included in the study. In accordance with GOLD guidelines the subjects were classified as COPD if FEV 1 /FVC was <70%.
Statistical analysis
Descriptive statistics (i.e. means, standard deviations, percentages) were applied to summarize the continuous and categorical variables. The relationship between two continuous variables was determined by measuring the Pearson's correlation coefficient. Overall differences among the three groups of patients (Overlap, COPD, OSAS) were tested by the ANOVA; the Tukey post-hoc analysis with the Spjotvol/Stoline test for unequal sample was performed to assess differences between each group. The student's t-test for dependent samples was used to assess differences over time in blood gas values or BMI according to long-term CPAP compliance. Multiple linear regression was used, both for the total group and the three subgroups, independently. Statistical Software (Statistica version 8.0, StatSoft, Inc. 2007, USA), was used to analyze the data.
Results
In accordance with the inclusion criteria 720 patients were selected for analysis. 466 (65%) were affected by OSAS without COPD (OSAS group); 86 (12%) patients were only COPD and not OSAS (COPD group), while 168 (23%) patients had both diseases (OS group). OSAS patients were younger than the OS who were younger than the COPD patients. No differences regarded BMI in OSAS vs OS but both had a higher BMI than COPD. The COPD group had a more severe obstructive disease than the OS ones (FEV 1 /FVC and FEV 1 were lower in COPD than in OS). In the OS group the percentage of sleep time with SaO 2 below 90% (T90) was higher than in the OSAS group. Interestingly, even if OS were younger and had better pulmonary functions than COPD, no differences were found regarding gas exchange for diurnal PaO 2 , PaCO 2 , or regarding 6MWT, while these values were lower than in OSAS patients (see Table 1 for more details).
The correlation coefficients between age, BMI, AHI, T90, and PaO 2 for each group are shown in Table 2 . The relationship between diurnal PaO 2 and other parameters were different in each group. Indeed, in OSAS patients PaO 2 was linked with Age, BMI, AHI, BMI, and FEV 1 , even if the higher coefficient was to do with T90 and BMI. In patients with COPD only the FEV 1 showed a negative correlation with diurnal PaO 2 . Finally in OS, as in OSAS, PaO 2 was linked with all the parameters analyzed except BMI, but the highest coefficient was found with T90. Regarding 6MWT no parameters were linked with it in COPD, whereas there was a correlation with age and diurnal PaO 2 in OS, while in OSAS only age had a negative correlation.
The results were substantially confirmed by multiple regression analysis. PaO 2 in the OSAS group was strongly related with BMI and age but less than with T90. In OS T90 and FEV 1 were more important, while in COPD only FEV 1 was linked with PaO 2 . 6MWT, on the other hand, was connected with age and BMI but only in the OS group, while in OSAS and COPD no parameters were linked with it ( Table 3) .
Ninety patients (55 OSAS and 35 OS) had a control visit and a new blood gas analysis one year after baseline; thus only for these people was it possible to verify whether nocturnal fixed CPAP can improve gas exchange. The patients were divided into two groups according to their referred use of CPAP, and only when it was possible by download of information from devices. Patients reporting that they hadn't ever or had used CPAP scantily were assigned to a "non-compliance" group, while patients who reported daily machine use were classified as "good compliance". At baseline no differences existed between the two groups as regards BMI, severity of sleep disorder and lung function, while PaO 2 was lower in the good compliance group. After one year all the subjects with good compliance had an improvement of diurnal PaO 2 and PaCO 2 , while the patients not using CPAP showed a worsening of PaO 2 and no change in PaCO 2 . These results were true both for OSAS and OS patients, even if in "no compliance" OS there wasn't any variation in gas exchange, although there was an improvement in the compliance group for PaO 2 and PaCO 2 . Further, in "no compliance" OSAS there was a worsening of PaO 2 , while daytime PaO 2 improved in compliance patients, no change being observed in PaCO 2 . (Table 4 , Fig. 1 ). In patients who needed an O 2 supplement during night use of CPAP, the addition of O 2 wasn't sufficient to improve PaO 2 if the patient had no compliance with CPAP (data not shown).
Discussion
The main result of this study lies in the number of apnea and hypopnea (AHI) per se not influencing daytime PaO 2 , while a strong relevance could be due to nocturnal desaturation expressed as T90, which is more true in patients with OS than in those who have only OSAS, where age and mostly BMI seem to have a more relevant role. This study demonstrated that many parameters can play an important role in influencing diurnal PaO 2 , though it seems that the models which can explain this relationship are different in patients with OS than in solely OSAS (Fig. 2) .
Lastly, another important result of this study is that nocturnal use of CPAP can improve diurnal PaO 2 not only in overlap patients but also in OSAS ones.
Previous studies have shown that patients with OSAS have a lower level of diurnal PaO 2 compared with normal subjects, but the causes of daytime hypoxemia are not totally clear. The presence of pulmonary hypertension, by pulmonary vasoconstriction, has been identified as the main condition which can contribute to reducing the oxygen level in arterial blood. 11, 12 In a large-scale study, Peppard and co-workers found that BMI is the most important predictive factor of the severity of oxygen desaturation during apnea or hypopnea. 13 Change in lung volume and, in particular, the reduction of functional reserve capacity (FRC) associated with higher body requirement of oxygen 14 could be the main mechanisms by which nocturnal desaturation is deeper in obese patients than in lean ones. 15 Besides the increase of airway resistances 16 and reduction of lung ventilation during sleep and mostly in REM stage, 17 there is also a worsening of ventilation/perfusion mismatching and then as regards SaO 2 .
One interesting result of this study is that in patients with overlap syndrome day-time hypoxemia seems to be due to a slightly different mechanism. Indeed, even if in OS diurnal PaO 2 is lower than in OSAS, in this case the BMI is not correlated with diurnal PaO 2 , while nocturnal hypoventilation is strongly correlated with low levels of PaO 2 .
Different mechanisms are involved in the pathogenesis of hypoventilation during sleep in COPD patients. First of all, during sleep there is a further reduction of FRC and an increase of closing volume, which is associated with mucus accumulation in the airways, worsening the ventilation/ perfusion mismatch. Moreover, in particular during REM sleep, the abolition of intercostal and accessory muscle activity is poorly supported by a good diaphragmatic contraction, which is impaired in these patients, 18 hence the final result is the relevant reduction of minute ventilation. 19 When OSAS and COPD are present together, as in OS, the result is a deeper desaturation and a higher time with SaO 2 under 90% during sleep.
Sands and co-workers 20 have shown that SaO 2 desaturation is deeper when repetitive apneas occur because venous hypoxemia subsequent to apnea can fast deplete Overlap syndrome predisposes to day-time hypercapnia and hypoxemia independently of lung function alone, 21 Moreover, COPD is frequently complicated by the development of pulmonary hypertension, 22 especially in patients with OS in whom pulmonary hypertension is frequent 23 because in this case alveolar hypoxia, one of the most important mechanisms leading to pulmonary arterial vasoconstriction and pulmonary hypertension, 24 is usually more pronounced. Our results confirm these observations; moreover, even if our patients with OS have the same PaO 2 and PaCO 2 as patients with only COPD these ones were older, leaner and have a worse lung function, indicating that it is very likely that nocturnal impairment is the cause of lower PaO 2 , as suggested by multivariate analysis.
Our analysis shows that there aren't any substantial differences as regards exercise performance, evaluated simply by 6MWT, between OS and COPD, even though, as expected, patients with only OSAS have a better performance.
Finally, recent randomized control trials show that inpatients with COPD nocturnal non-invasive ventilation (NIPPV) associated with pulmonary rehabilitation can improve their quality of life and gas exchange compared to pulmonary rehabilitation alone. 25 Indeed, even if our study Table 3 ). According to multivariate analysis diurnal PaO 2 in OSAS is mostly related with BMI and AGE, while nocturnal hypoventilation (expressed as T90) is more important in OS. In patients with COPD, with any nocturnal problems, PaO 2 is related only with severity of disease evaluated by FEV 1 impairment.
is differently designed, the results are in line with these data because our patients were all on the pulmonary rehabilitation program, though only the patients who were compliant to nocturnal ventilation, mostly CPAP, had obtained and improvement of gas exchange. The mechanism able to explain this observation could be different, including: reduction of pulmonary subclinical edema, reduction of upper resistances, more lung work and a reduction of ventilation/perfusion mismatch, better muscle efficiency, an increase in alveolar ventilation and then a reduction of vasoconstriction, etc. The administration of nocturnal oxygen in patients with sleep hypoventilation seems to be insufficient to improve day-time PaO 2 ; indeed, it is still a matter of debate whether this therapy has a positive effect on survival or not. 26 Our data show that CPAP has a more positive impact on improvement of diurnal PaO 2 , independently of the addition of oxygen. Thus we can speculate that nocturnal ventilation, both when it is a consequence of OSAS alone and moreso when there is an association of OSAS and COPD, should be preferred to oxygen alone in order to improve gas exchange and perhaps a patient's quality of life and survival. However, even if it might seem superfluous, it is important to underline that only a continued use of CPAP is really useful to obtain a good result.
A strong point of this study lies in the large number of patients that we included in this retrospective analysis even if some limitations must be underlined: the most serious is that only some of the patients who were referred to our institutes underwent spirometry and blood gas analysis without a specific criteria and so this could represent a bias in the selection of population; indeed, it is for this reason that a prospective study should be done in order to confirm our results.
In conclusion, our results seem to support the hypothesis that diurnal PaO 2 is the result of a mix of factors (BMI, T90, FEV 1 ) rather than being the cause of the severe nocturnal desaturation. The mechanisms which determine the daytime level of PaO 2 seem to vary in patients with OSAS alone with respect to those who have OSAS and COPD in whom nocturnal hypoventilation is more pronounced and has a great impact on diurnal PaO 2 . Finally, it is worth noting that CPAP, when correctly administrated, can improve gas exchange and have a positive effect on the life of patients with sleep-disordered breathing.
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